Evidence map›Paper›PMID 28035370›Full record

ArticleInternational journal of oncology2017

Induced overexpression of CD44 associated with resistance to apoptosis on DNA damage response in human head and neck squamous cell carcinoma cells.

Emika Ohkoshi, Naoki Umemura

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Modulation ofInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Advances in Anti-Cancer Activities of Flavonoids inInternational journal of molecular sciences · 2022
    Review
  6. Chiral Flavonoids as Antitumor Agents.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Emika OhkoshiDepartment of Natural and Medicinal Chemistry, Faculty of Pharmaceutical Sciences Aomori University, Aomori, Aomori 030-0943, Japan.
Naoki UmemuraDepartment of Oral Biochemistry, Asahi University School of Dentistry, Gifu 501-0296, Japan.
Aomori University · JPAsahi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD44 is a marker of cancer stem cells in head and neck squamous cell carcinoma, and CD44 expression is related to prognosis in cancer patients. We examined whether herbal medicine components affect CD44 expression and induce cancer cell apoptosis. Baicalin enhanced apoptosis with no effect on CD44 levels, while baicalein did not enhance apoptosis and upregulated CD44 in head and neck squamous cell carcinoma. Furthermore, baicalein induced phosphorylation of CHK1, as a marker of DNA damage response to S-to-G2/M phase arrest. Our results clearly demonstrated that baicalein enhanced expression of CD44 and accordingly enhanced the DNA damage response. These data suggest that induction of CD44 inhibited cancer cell induction of apoptosis by increasing the DNA damage response. Together, our findings suggest that CD44 expression in head and neck squamous cell carcinoma plays a role in enhancing the DNA damage response.

Indexed as

ApoptosisCarcinoma, Squamous CellCell Line, TumorDNA DamageEnzyme InhibitorsFlavonoidsFluorescent Antibody TechniqueHead and Neck NeoplasmsHumansHyaluronan ReceptorsImmunoblottingMedicine, Chinese TraditionalNeoplastic Stem CellsSquamous Cell Carcinoma of Head and NeckbaicalinCD44 protein, humanEnzyme InhibitorsFlavonoidsHyaluronan Receptors

Identifiers

PMID28035370
PMCPMC5238781
OpenAlexW2562531557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.